US 11,951,125 B2
Drug and production method therefor
Hikaru Kobayashi, Osaka (JP); Yuki Kobayashi, Osaka (JP); Ryoichi Imamura, Osaka (JP); and Norio Nonomura, Osaka (JP)
Assigned to OSAKA UNIVERSITY, Osaka (JP)
Filed by OSAKA UNIVERSITY, Osaka (JP)
Filed on Apr. 21, 2021, as Appl. No. 17/236,891.
Application 17/236,891 is a continuation of application No. 16/633,807, granted, now 11,103,527, previously published as PCT/JP2018/025315, filed on Jul. 4, 2018.
Prior Publication US 2021/0275578 A1, Sep. 9, 2021
Int. Cl. A61K 33/00 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61P 13/12 (2006.01)
CPC A61K 33/00 (2013.01) [A61K 9/0053 (2013.01); A61K 9/167 (2013.01); A61P 13/12 (2018.01)] 14 Claims
OG exemplary drawing
 
1. A drug for a disease of a kidney, comprising one or more of (a), (b) or (c):
(a) an aggregate of silicon fine particles, the aggregate having a size of more than 0.1 μm;
(b) a crystal grain of silicon, the crystal grain having a particle size of about 1 μm to about 2 μm, and
(c) one or more hydrogen generating material selected from the group of:
porous silicon fine particles having a size of more than 100 nm,
polycrystalline silicon fine particles having a size of more than 100 nm,
unfree silicon fine particles having a size of more than 100 nm,
hardly crushed silicon fine particles having a size of more than 100 nm,
silicon fine particles having a size of more than 100 nm and granulated with an undecomposed binding agent, and
a porous crystal grain of silicon, the porous crystal grain having a size of more than 100 nm,
wherein hydrogen is generated by bringing a water-containing liquid in an intestine into contact with the aggregate of silicon fine particles, the crystal grain of silicon or the one or more hydrogen generating material.